The pathogenesis of many diseases is driven by the interactions between helper T (T H ) cells and macrophages. The phenotypes of these cells are functional dichotomies that are persuaded according to the surrounding milieu. In both multiple sclerosis and the experimental autoimmune encephalomyelitis (EAE) model, T H 1 and T H 17 cells propagate autoimmune signaling and inflammation in the peripheral lymphoid tissues. In turn, this proinflammatory repertoire promotes the classical activation, formerly the M1-type, macrophages. Together, these cells infiltrate into the central nervous system (CNS) tissues and generate inflammatory and demyelinating lesions. Our most recent report demonstrated the immunomodulatory and antiinflammatory effects of adipose stromal vascular fraction (SVF) cells and adipose-derived stem cells (ASCs) that led to functional, immunological, and pathological improvements in the EAE model. Here, a deeper investigation revealed the induction of regulatory T cells and alternative activation, or M2-type, macrophages in the periphery followed by the presence of alternative activation macrophages, reduced cellular infiltrates, and attenuation of neuroinflammation in CNS tissues following intraperitoneal administration of these treatments. Spleens from treated EAE mice revealed diminished T H 1 and T H 17 cell activities and were markedly higher in the levels of anti-inflammatory cytokine interleukin-10. Interestingly, SVF cells were more effective than ASCs at mediating these beneficial changes, which were attributed to their localization to the spleens after administration. Together, SVF cells rapidly and robustly attenuated the propagation of autoimmune signaling in the periphery that provided a permissive milieu in the CNS for repair and possibly regeneration. STEM CELLS 2017;35:2198-2207 
INTRODUCTION
Understanding the pathological mechanisms underlying inflammation and autoimmunity are of great importance as these are common features shared by many diseases. When these immune-mediated activities lead to pathology within the central nervous system (CNS), the damage can render a CNS milieu that is insufficient for repair [1, 2] . Multiple sclerosis (MS) is a common autoimmune, neurodegenerative disease that remains an unmet clinical challenge. Although the etiology is unclear, it is accepted that an autoimmune response in the peripheral lymphoid tissues is elicited against myelin, the protein sheath produced by oligodendrocytes that insulates nerve axons in the CNS [2] [3] [4] . Autoimmune signaling causes effector T cells and macrophages to be recruited across the blood-brain barrier and infiltrate into CNS tissues where they generate inflammatory and demyelinating lesions predominantly in areas of white matter [3] [4] [5] [6] [7] [8] . Using the widely accepted murine experimental autoimmune encephalomyelitis (EAE) model of MS, many of the immunological and pathological features can be reproduced for preclinical investigations [4, 6, 9] .
Our laboratory has reported the therapeutic effects of fresh adipose stromal vascular fraction (SVF) cells and cultureexpanded adipose-derived stem cells (ASCs) in the EAE model [10] [11] [12] [13] . Recently, we extensively characterized freshly isolated SVF cells and culture-expanded ASCs from murine donors and compared the therapeutic efficacies when administered at late-stage EAE disease. The main subpopulations that comprise the fresh SVF cells were CD34
1 cells (12.48%), ASCs (9.92%), CD3 1 T cells (7.57%), adipocytes (6.43%), and macrophages (5.50%). We showed the ability of the SVF cells and ASCs to modulate immune cell activities and improve CNS pathology that partially restored motor function at late-stage disease [11] . With this study, we further demonstrated the cellular mechanisms that mediated these alterations to the phenotypes of helper T (T H ) cell and macrophages in the periphery that attenuated pathology in the CNS. Most importantly, analysis of the spleens and CNS tissue 5 days following treatment with SVF cells or ASCs indicated that both treatments greatly attenuated the activities of T H 1 and T H 17 cells and their associated proinflammatory cytokines. A marked increase in interleukin-10 (IL-10) was correlative to an increased regulatory T cells (Tregs) in the periphery. In turn, this immunomodulation provided a favorable repertoire to induce alternative activation macrophages, previously coined M2, which produced reparative effects in the CNS. Together with our previous reports, SVF cells and ASCs have demonstrated a strong potential for repair and possibly regeneration in the CNS. Moreover, our data demonstrate the use of this easily obtained, uncultured, heterogeneous SVF cells as a therapeutic alternative to culture-expanded ASCs with comparable therapeutic efficacy which has a high impact for many other human indications.
MATERIALS AND METHODS

EAE Induction Using Myelin Oligodendrocyte Glycoprotein 35-55 Peptide
Reagents for EAE induction were prepared by dilution of myelin oligodendrocyte glycoprotein Technologies) , and 2 mM L-glutamine (Life Technologies). Digested tissue was filtered through a sterile gauze and centrifuged to obtain the pellet of SVF cells. For the isolation of ASCs, SVF cells were plated in 15 cm culture dishes containing CCM, which was incubated at 378C with 5% humidified CO 2 . After 24 hours, plates were washed of non-adherent cells with PBS, and fresh CCM was added to each plate. When 70% confluence was achieved, cells were passaged by trypsinization with 0.25% trypsin/1 mM EDTA (Gibco), neutralized with v/v CCM, centrifuged, and re-seeded onto culture dishes at a density of 100-200 cells per square centimeter. This process was repeated for subsequent passages then cells were cryopreserved before experimental use.
Preparation and Injection of Cells
Based on past EAE studies, the day for late-stage therapeutic administration was designated as 20 days post induction (DPI) when motor impairment is greatest and lesions are disseminated throughout the CNS. At 20 DPI, PBS was used to wash freshly isolated SVF cells and cryopreserved ASCs (passage 3-4) before injection. Cells were counted using a trypan blue exclusion method on a hemocytometer. Subsequently, ASCs and SVF cells were re-suspended in HBSS at concentrations of 10 7 cells/ml and transferred to 1 ml Leur-Lok syringes with 27G 1 =2 inch needles. EAE mice were randomly designated to treatment groups: ASC treatment, SVF treatment, or vehicle control groups, and received an i.p. injection of 100 ml containing 10 6 ASCs, 10 6 SVF cells, or HBSS, respectively. Harvested spleens were mechanically digested through cell strainers using the blunt ends of syringes. The cells were then incubated with red blood cell lysis for 5 minutes at RT. Following, the splenocytes were washed with PBS and counted. Splenocytes were then processed for flow cytometric analysis or stored at 2808C for RNA isolation.
Flow Cytometric Staining and Analysis. CNS cells and splenocytes were counted using a hemocytometer and prepared in staining buffer containing 1% BSA and 1% CD16/CD32 Mouse BD Fc Block (BD Biosciences). Next, cells were stained with fluorescently conjugated anti-mouse antibodies against CD3, CD4, CD45, CD11b, CD11c, CD86, and CD206 (eBioscience). Designated samples were incubated in a fixation/permeabilization solution (eBioscience), stained with a fluorescently conjugated anti-mouse antibody against intracellular foxp3, washed, and stored in buffer solution. All other samples were fixed using 1% paraformaldehyde, washed and stored in buffer solution. The samples were stored at 48C until further analysis.
Flow cytometric analysis of each sample was performed using a BD LSRFortessa (BD Biosciences) instrument. Data analysis was acquired of 10,000 events using FlowJo software (FlowJo, LLC, Ashland, OR, http://www.flowjo.com) for representative samples in each group (n 5 4).
RNA Isolation from CNS Tissue and Spleens. Briefly, Qiazol Tissue Protectant (Qiagen, Valencia, CA, http://www.qiagen.com) was added to cells isolated from the CNS tissues and spleens. Total RNA extraction was performed for each sample using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. RNA was subsequently purified with DNase I (Invitrogen) and 1 mg RNA was reverse transcribed using the SuperScript VILO cDNA synthesis kit (Invitrogen). EXPRESS SYBR GreenER qPCR SuperMix Kit (Invitrogen) was used for quantitative reverse transcriptase polymerase chain reaction (qPCR) using mouse-specific primers to IL-2 receptor forward 5
0 , and eGFP forward 5 0 -GGGCACAAGCTGGAGTA CAAC-3 0 , reverse 5 0 -CACCTTGATGCCGTTCTTCTG-3 0 . All other primer sequences were previously reported [11] . For GFP detection, qPCR data were calculated and reported as the log (-DCt) to represent the levels of GFP mRNA. All other qPCR data were calculated and reported as the DDCt values that were normalized to the vehicle control group for quantitative comparison of mRNA expression levels. Values were represented as the mean 6 SEM of the relative fold change for each group (n 5 3).
Histological Analysis of Spinal Cords. Formalin fixed cervical spinal cords were paraffin-embedded, cut 5 microns thick, and mounted on microscope slides. Sections were stained with H&E (Richard-Allan Scientific, Thermo Fisher Scientific) and scanned into Imagescope software (Aperio Technologies, Inc., Vista, CA, http://www.leicabiosystems.com) using an Aperio Scanscope CS2 instrument (Aperio Technologies, Inc.). For each section, three images of randomly selected fields of white matter were taken at 40X magnification. Each image was then uploaded onto Fiji/Image J software (National Institutes of Health, Bethesda, MD, https://imagej.nih.gov) and cells were counted according to the number of pixels and circularity. For each mouse section, 3 fields were measured for cellular infiltrates per group (n 5 5).
Additional sections were used for immunohistochemical analysis. Briefly, sections were de-paraffinized, rehydrated, and heat-mediated antigen retrieval was performed. Sections incubated with blocking solution containing: 10% goat serum, and 1% BSA in Tris buffered solution (TBS), for 1 hour at RT. Designated sections were then stained with primary antibody rat anti-mouse glial fibrillary acidic protein (GFAP; 1:200, Life Technologies) followed by secondary goat anti-rat IgG Alexa Fluor 594 (Invitrogen Molecular Probes, Eugene, OR, http:// www.thermofisher.com/invitrogen). Rat anti-mouse primary antibodies F4/80 (Invitrogen) and goat anti-mouse Arginase-1 (Arg-1; 1:200, Santa Cruz Biotechnology, Dallas, TX, https:// www.scbt.com) were prepared in staining buffer containing 1% BSA in TBS and incubated on spinal cord sections overnight at 48C. Sections were then washed and incubated with secondary antibodies: goat anti-rat IgG Alexa Fluor 488 (Invitrogen Molecular Probes) and donkey anti-goat IgG Alexa Fluor 647 (Abcam, Cambridge, MA, http://www.abcam.com) for 1 hour at RT. Additional washes were then followed by mounting with ProLong Gold anti-fade reagent with DAPI (Life Technologies) and a coverslip. Images were taken at 40X magnification along the perivascular regions of the spinal cords using a Nikon Eclipse E800 (Nikon, Melville, NY, http://www.nikon.com) microscope with Slidebook version 5.0 software (Olympus, Center Valley, PA, http://www.olympusmicro.com).
Detection of Serum Proteins
Using an Enzyme-Linked Immunosorbent Assay. Sera stored at 2808C were thawed and equal amounts were pooled together to represent samples for each group (n 5 7). Samples were added to the wells of an ELISArray plate of the Mouse Th1/Th2/Th17 Cytokines 2200 SVF Cells Promote Immunomodulation and Repair
Multi-Analyte ELISArray Kit (MEM-003A; SABiosciences, Qiagen) and processed according to the manufacturer's protocol. The plate was read at absorbance (450 nm) and values were corrected by subtraction of the negative control values.
Statistical Analysis
All values reported for the SVF-, ASC-, and vehicle-treated EAE mice were quantitatively compared with the sham control group. Statistical analyses were performed using one-way analysis of variance followed by pairwise comparisons of the mouse groups using Bonferroni post hoc testing. Significance for the overall group effect and individual pairwise comparisons were made against the sham-treated EAE group and defined as p < .05. Analysis was performed using Prism 5.0 (Graphpad Software, La Jolla, CA, https://www.graphpad.com).
RESULTS
SVF Cells and ASCs Reduce the Levels of Cellular Infiltrates in the Spinal Cords
Cervical spinal cord sections were stained with H&E to visualize the presence of cells within the white matter (Fig. 1A) . Quantitative comparison with sham controls (79.5 6 25.02 cells) determined significantly higher levels of infiltrates higher levels of cellular infiltration in the vehicle treated EAE group (166.2 6 58.4 cells; p < .001) and improvements to the levels of infiltrates 5 days following injection of SVF cells (115.3 6 59.8 cells) and ASCs (109.3 6 39.9 cells; Fig. 1C ). Representative images of spinal cord sections stained with GFAP demonstrated the level of astrogliosis associated with neuroinflammation among all groups. Reduced GFAP staining suggested that after 5 days of treatment with SVF cells and ASCs, attenuation of neuroinflammation occurred (Fig. 1B) . The frequency of activated myeloid cells defined by the expression of CD11b Alternative activation macrophages were detected at higher frequencies 5 days after treatment in the SVF-treated (1.82% 6 0.45%; p < .05) and ASC-treated (2.09% 6 0.46%; p < .05) EAE mice compared with the vehicle-treated EAE mice (1.42% 6 0.15%) and sham controls (0.40% 6 0.03%). In contrast, the levels of the classical activation phenotype of macrophages 5 days following SVF treatment (0.32% 6 0.44%) were comparable with the vehicle-treated (0.28% 6 0.53%) and sham control (0.17% 6 0.02%) EAE mice, while an increase was detected 5 days following treatment with ASCs (0.44% 6 0.10%; p < .05; Fig. 2B ). Gene expression levels of enzymes Arg-1 and induced nitric oxide synthase (iNOS) associated with the polarization of phenotype to either the alternative or classical activation macrophage, respectively, were indicated in the CNS 10 days following treatment. Gene expression levels of Arg-1 and induced nitric oxide synthase measured in the CNS tissues of mice in each group showed SVF treatment induced the largest changes to macrophage phenotypes 10 days after treatment. Scale bars 5 50 mm. *, p < .05; **, p < .01; ***, p < .001 compared with sham-treated EAE group. Abbreviations: ASC, adipose-derived stem cell; EAE, experimental autoimmune encephalomyelitis; SVF, stromal vascular fraction.
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V C AlphaMed Press 2017 most significantly and comparably reduced 5 days following administration of treatment. Similarly, but to a lesser extent, the frequencies of T H cells within the spleen 5 days following SVF treatment were marked reduced (11.39% 6 2.41%; p < .01) compared with the sham controls.
At 25 DPI, the frequency of splenic Treg populations of the sham controls was 4.54% 6 0.38%. By comparison, the frequencies of Tregs in all EAE groups were significantly reduced 5 days following treatment. Amongst the EAE groups, the Tregs within the spleens of SVF-treated mice (1.67% 6 0.22%; p < .001) were highest compared with the vehicle-(1.35% 6 0.09%; p < .001) and ASC-treated (1.33% 6 0.16%; p < .001) mice, respectively (Fig. 3B) .
Alternative Activation Macrophages Were Rapidly Induced in the Spleens Following SVF Treatment. The expression levels of Arg-1, which are associated with the alternative activation macrophages, were measure 5 and 10 days after treatment. The highest levels of Arg-1 were measured in splenocytes 5 days after treatment with SVF cells (3.56 6 1.01-fold; p < .05) compared with those in EAE mice treated with vehicle (1.02 6 0.16-fold) and ASCs (1.70 6 0.09-fold) or sham controls (0.34 6 0.14-fold). At 10 days after treatment, levels of Arg-1 were highest in the spleens of EAE mice treated with ASCs (2.73 6 1.6-fold), followed by treatment with SVF cells (1.52 6 0.34-fold), vehicle (1.10 6 0.36-fold), and sham controls (0.10 6 0.04-fold; Fig. 4A ). The expressions of iNOS in the spleens were highly variable for all mice in each group and consequentially unable to achieve statistical comparisons (data not shown).
SVF Cells and ASCs were Detected in the Spleens 5 Days Following Treatment. Cells used as treatment in this study were isolated from GFP-expressing transgenic mice and then administered to EAE mice via i.p. injection. After 5 days, GFPexpression was analyzed within harvested spleens to determine whether injected cells were still present. Evidence determined that ASCs (6.01 6 0.88 3 10 4 ) and an even markedly higher presence of GFP was detected in the EAE group treated with SVF cells (2.26 6 0.40 3 10 3 ; p < .001). The levels of GFP were undetectable in the vehicle-treated EAE group and sham controls (Fig. 4B) . To determine the presence of T H 1 and T H 17 cells in the spleens 5 days following treatment, the expression levels of interferon-g (IFNg), IL-23, IL-12, and IL-17 were analyzed. For the levels of IFNg, EAE mice treated with SVF cells (0.58 6 0.23-fold) and ASCs (0.51 6 0.09-fold) and sham controls (0.59 6 0.15-fold) were comparably less compared with the vehicle-treated EAE group (1.16 6 0.39-fold). The levels of IL-23 were markedly reduced in the sham controls (0.001 6 0.0004-fold) and EAE mice following treatment with SVF cells (0.23 6 0.05-fold) and ASCs (0.10 6 0.04-fold) compared with the vehicle-treated EAE mice (1.13 6 0.33-fold; p < .01). Similarly, the levels of IL-12 were reduced in the SVF-(0.80 6 0.15-fold) and ASC-treated (0.26 6 0.09-fold) EAE mice and higher in the vehicle-treated EAE group (1.13 6 0.41-fold; p < .05) compared with the sham controls Proteins in Circulation Showed Evidence Consistent to the Expression Levels of Cytokines Detected in the Spleens. The protein levels of inflammatory mediators that correspond to T H cell subsets were detected in the pooled sera of mice 5 days following treatment. Tumor necrosis factor (TNF)-a levels were highest in the vehicle-treated EAE group (0.012 OD) followed by the sham controls (0.09 OD) and ASC-treated EAE group (0.03 OD). The levels of TNF-a were reduced to undetectable levels in the SVF-treated EAE group. Likewise, SVF treatment reduced the levels of IL-17 to undetectable levels compared with the vehicle-(0.13 OD) and ASC-treated (0.14 OD) and sham controls (0.09). Moreover, the protein levels of IL-23 were lowest in the SVF treatment group (0.05 OD) followed by the vehicle-(0.13 OD) and ASC-treated (0.15 OD) EAE mice and sham controls (0.08 OD). Consistent with the gene expression levels detected in the spleens, the protein levels of TGF-b were highest in the EAE mice treated with SVF cells (0.20 OD) and ASCs (0.18 OD) and sham controls (0.11 OD) compared with the vehicle-treated EAE group (0.001 OD; Fig. 6 ).
SVF Cells and Not ASCs Promoted the Expansion of T Cells Sug
DISCUSSION
In both MS and EAE, effector T cells and macrophages are activated in peripheral lymphoid organs, migrate through the bloodstream, and infiltrate into CNS tissues where they [14] [15] [16] [17] [18] [19] . These inflammatory mediators not only incite neuroinflammation but also direct the differentiation and maintenance of the classical activation macrophage phenotype [20, 21] . During the progression of EAE, macrophages express the classical activation phenotype that additionally release proinflammatory cytokines and damage CNS tissue [21, 22] . Enhancing this proinflammatory phenotype of macrophages showed further aggravation of CNS disease in EAE [22] . Together, this signaling axis between the effector T cells and macrophages are prime targets of immunomodulatory therapies in order to prevent further pathology [23] [24] [25] . The functional dichotomy of macrophage phenotypes, termed as the classical activation and the alternative activation phenotypes, is not definitive, but dynamic, and is dependent on the milieu [20, 23] . Much is evidenced about the T H 1 cell-derived IFNg that directs the classical activation macrophage that functions as proinflammatory [23, 24, 26] . On the contrary, T H 2 cells and Tregs produce IL-4 and IL-10, respectively, which are capable of promoting the alternative activation macrophage phenotype. Increasing evidence has now shown that IL-10 has a more robust effect on inducing alternative activation phenotype of macrophages [27, 28] . Furthermore, many immune cells are capable of expressing IL-10, including Tregs and alternative activation macrophages which, in turn, further increase the levels of IL-10 and promote the differentiation of additional regulatory cells. Together, this establishes an anti-inflammatory milieu capable of suppressing effector T cell functions [28] [29] [30] . Aside from producing IL-10, alternative activation macrophages are critical for promoting reparative and anti-inflammatory effects [24, 28, 31] . Together, many approaches to shift the phenotype of macrophages from classical to alternative activation have been executed that demonstrate substantial improvements in EAE [20, 25, 28, 30] . Our previous study demonstrated comprehensive therapeutic effects of SVF cells and ASCs 10 days after treatment. Induction of Tregs and high levels of IL-10 were measured highest in the peripheral blood and lymphoid tissues following SVF and ASC treatments which was correlative to reduced cellular infiltrates and increased levels of myelin in the CNS. In this study, we analyzed these same tissues 5 days after treatment in order to gain a better understanding that mediated these changes following the treatments. Our data suggest that treatment with ASCs and, more robustly, SVF cells mediated improvements by shifting the T H cell and macrophage paradigm. This data showed that in multiple tissues cytokines IFNg, IL-12, IL-23, and IL-17, which are secreted by T H 1 and T H 17 cells, were attenuated following treatment with SVF cells and ASCs. This coincided with a reduction in inflammatory infiltrates and astrogliosis associated with neuroinflammation in CNS tissues.
Moreover, the increased presence of alternative activation macrophages along with high levels of Arg-1 were measured in both the spleens and CNS tissues of EAE mice treated with SVF cells and ASCs. The data suggested that SVF cells promoted a more rapid and robust induction of alternative activation macrophages in the spleens compared with the ASCs. Marked increases in IL-10 and Arg-1 levels were measured in the spleens of EAE mice directly after the administration of SVF cells. Although the expression levels of IL-4 were diminished with SVF and ASC treatments, the analysis 5 days following treatment may not have allowed for detection of T H 2 differentiation. Similarly, at this time, a modest increase in Tregs was observed in the spleens following treatment with SVF cells, and our previous reports showed a more robust induction of Tregs and associated IL-10 at 10 days following treatment.
Growing evidence is suggesting that the dynamic polarization and correlative functions of microglia, the resident macrophages of the CNS, are similar to those of peripheral macrophages [21, 32] . As immune cells of the CNS, microglia can be activated and, depending on the cytokine repertoire, have been shown to either promote propagation of neuroinflammation or play a role in immunosuppression by suppression of T H 17 cells in EAE [21, [32] [33] [34] . Together, this evidence correlates the immunomodulatory potency of SVF cells and ASCs in the periphery that are transmitted to the CNS to attenuate neuroinflammation and pathology and mediate repair in EAE (Fig. 7) .
CONCLUSION
Currently, fresh SVF cells can be isolated from harvested adipose to supplement fat grafts or used cosmetically during plastic and reconstructive procedures. Adipose can be easily digested, and the SVF cells can be rapidly administered back to patients without the need for laboratories and equipment for culture expansion [35, 36] . Although uncultured SVF cells is proposed as an attractive alternative to culture-expanded ASCs, this heterogeneous composition that contains various leukocytes expressing self-antigens could have detrimental effects. With the translational implications for using fresh SVF cells for therapeutic purposes, it is suggested that autologous administration of SVF cells remains the safest method of use.
